10.23.18
Velesco Pharma, a pharmaceutical development and clinical manufacturing company, has expanded and enhanced its formulation and analytical research and development capabilities with the acquisition of a new facility in Wixom, MI. The acquisition and fit-out of this new facility doubles Velesco’s formulation and analytical lab space, allowing for expansion of services.
Velesco Pharma will continue to offer both research and cGMP services including formulation development, analytical method development/validation, release and stability testing and cGMP clinical manufacturing. The move of Velesco Pharma’s lab to the expanded facility will take place by the end of the year.
“Our new laboratory is impressively designed and equipped, and we will be increasing our scientific team such that we can meet our clients’ growing demand for pharmaceutical formulation and analytical services,” said Dave Barnes, Ph.D., chief executive officer at Velesco. “We look forward to opening the doors of our new center of excellence and collaborating with our current and new clients to ensure the quality and responsiveness their drug development programs demand.”
Velesco Pharma will continue to offer both research and cGMP services including formulation development, analytical method development/validation, release and stability testing and cGMP clinical manufacturing. The move of Velesco Pharma’s lab to the expanded facility will take place by the end of the year.
“Our new laboratory is impressively designed and equipped, and we will be increasing our scientific team such that we can meet our clients’ growing demand for pharmaceutical formulation and analytical services,” said Dave Barnes, Ph.D., chief executive officer at Velesco. “We look forward to opening the doors of our new center of excellence and collaborating with our current and new clients to ensure the quality and responsiveness their drug development programs demand.”
For more information visit Booth #2415 at AAPS PharmSci 360